Mapping The Dynamics Of Corneal Stem Cell During Aging And After Wounding And Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$548,403.00
Summary
Restoring vision in patients with corneal blindness is our focus. Before this can be achieved we need to understand how corneal stem cells function. For many reasons these studies cannot be performed in man, so we engineered a mouse in which the location, migration, division, differentiation, death of these cells can be followed indefinitely. This information will allow us to improve current therapeutic options and develop new clinical solution for patients with blinding corneal disease.
Cultivated Corneal Endothelial Cell Implants For Restoring Vision
Funder
National Health and Medical Research Council
Funding Amount
$886,032.00
Summary
Thousands of Australians each year receive a corneal tissue transplant from the eyes of a deceased organ donor. In the majority of cases these transplants are performed to restore structure and function to the most posterior layer of the cornea – the corneal endothelium. The reliance upon donor tissue, however, presents significant logistical and safety issues. Our goal is therefore to develop improved strategies for treating diseases of the corneal endothelium using cultivated tissue implants.
Modelling Leber’s Hereditary Optic Neuropathy Using Human Induced Pluripotent Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$628,416.00
Summary
Leber’s Hereditary Optic Neuropathy (LHON) is a blinding disease that affects young males and is caused by the death of cells in the optic nerve. To better understand LHON, this project utilises induced pluripotent stem (iPS) cells for disease modelling. iPS cells will be generated from patients and turned into optic nerve cells, allowing us to study the diseased cells in the laboratory, providing a platform to screen for novel drugs to improve treatment options and fast-track drug development.
Regulation Of ICAM-1 Expression In Human Retinal Endothelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$565,967.00
Summary
Posterior uveitis is an inflammation that occurs within the eye and may result in blindness. Present treatments are not directed specifically at the inflamed tissues, and they may be ineffective and cause toxicity. This research aims to identify molecules controlling the entry into the eye from the bloodstream of the white blood cells that cause the disease. The results should suggest new targets for safer drugs to treat patients with posterior uveitis.
A Novel Mesenchymal Stromal Cell And Biomaterial For Corneal Reconstruction
Funder
National Health and Medical Research Council
Funding Amount
$508,611.00
Summary
Our research group has identified a new cell type (L-MSC) with the potential to treat a variety of eye diseases. We have also developed a novel material from a protein found in silk, that has potential as a vehicle for delivering healthy cells into diseased eyes. The present project will build upon these promising results by evaluating the properties of L-MSC necessary for clinical use and by testing the feasibility of our new cell delivery system.
Anti-vascular Endothelial Growth Factor-B As A Biologic For Treating Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$464,295.00
Summary
We plan to show that an engineered antibody fragment against vascular endothelial growth factor-B is an effective therapeutic drug for two eye diseases, corneal neovascularization and age-related macular degeneration. The innovative aspects of this approach are that it may be safer, and have a different spectrum of activity, than existing ophthalmic anti-angiogenic agents. Furthermore, it may be effective for corneal disease when administered as an eye-drop.
A Non-cytotoxic Approach To Reduce Ocular Fibrosis Following Surgery In Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$586,979.00
Summary
Glaucoma surgery often leads to scar formation and blindness. We have identified a novel protein (NADPH oxidase 4; Nox4) which promotes scar formation in the eye. Lack of Nox4 in a mouse models reduces scar formation. We have demonstrated that a ‘repurposed’ drug which is currently used to treat lung diseases can also block Nox4 in the eye. We aim to determine whether this drug can be used as a novel therapy for vision loss after glaucoma surgery.
Targeting The De Novo Serine Synthesis Pathway In Macular Disease
Funder
National Health and Medical Research Council
Funding Amount
$628,084.00
Summary
We have found a significant difference in de novo serine metabolism between the human primary Müller cells isolated from macular and peripheral retinas. We will study whether and how this difference contributes to redox homeostasis in these areas. The outcomes will help us to gain a better understanding of why the macula is more prone to develop disease than the peripheral retina.